{
    "clinical_study": {
        "@rank": "73843", 
        "acronym": "CESAR", 
        "arm_group": {
            "arm_group_label": "Rosuvastatine 20 mg", 
            "arm_group_type": "Experimental", 
            "description": "Rosuvastatin 20 mg/day, once a day during 3 months"
        }, 
        "brief_summary": {
            "textblock": "Participating countries: France Objectives Principal objective To evaluate, in HIV-1\n      infected patients receiving effective antiretroviral therapy, the effect of the addition of\n      Rosuvastatin (dose of 20mg/day) for 3 months, on CD8 T cell activation as assessed by the\n      proportion of peripheral CD8 T cells that co-express the activation markers CD38 and HLA-DR\n      Secondary objectives To evaluate the effect of Rosuvastatin administration on residual CD4\n      and CD8 T cell activation To evaluate the effect of Rosuvastatin administration on the main\n      serum soluble biomarkers of activation (CRP- HS, D-dimers, IL-6 and soluble CD14) To\n      evaluate the effect of Rosuvastatin administration on CD4 T-cell count and on the CD4/CD8\n      T-cell ratio To study the relationship between the level of immune activation and the level\n      of residual HIV replication in plasma To study the effect of Rosuvastatin administration on\n      lipid profiles and the correlation between the HDL cholesterol and the CD4/CD8 T-cell ratio\n      To evaluate the tolerance of Rosuvastatin at the dose of 20 mg/day"
        }, 
        "brief_title": "Rosuvastatin to Decrease Residual Immune Activation in HIV Infection", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "HIV-1 Infection", 
        "condition_browse": {
            "mesh_term": "HIV Infections"
        }, 
        "detailed_description": {
            "textblock": "Methodology Phase II pilot study; open-label; non comparative, bicentric, on-off design\n\n      Estimated enrolment   40 subjects\n\n      Outcomes Primary outcome :\n\n      \u2022 Variation at month 3 in the proportion of CD8 T lymphocytes co-expressing CD38 and HLA-DR\n\n      Secondary outcomes :\n\n        -  Evolution of plasma/serum levels of CRP-HS, IL-6, soluble CD14 between baseline and\n           month 3 and between month 3 and month 6\n\n        -  Evolution of markers of CD4 T-cell activation (HLA-DR, Ki67) and CD8 T-cell activation\n           (CD38, HLA-DR, Ki67) between baseline and month 3 and between month 3 and month 6 and\n           evolution of the CD4/CD8 ratio between baseline and month 3 and between month 3 and\n           month 6\n\n        -  Evolution of CD4 T-cell count between baseline and month 3\n\n        -  Evolution of HDL and LDL cholesterol between baseline and month 3 and between month 3\n           and month 6\n\n        -  Relationship between HDL cholesterol and CD4/CD8 ratio at baseline, month 3 and month 6\n\n        -  Relationship between the levels of T-cell activation and of plasma HIV-RNA levels at a\n           detection level of 3 copies/mL\n\n        -  Adverse events grade > 2 Eligibility Inclusion criteria\n\n        -  HIV-infected patients receiving a combination of antiretroviral therapy for at least 24\n           months, unchanged since at least 18 months, exhibiting plasma HIV-RNA level below 20\n           copies and  circulating CD4 T cell count below 500/mm3\n\n        -  No indication for a treatment with statins (LDL cholesterol < 4.1 mmol/L under stable\n           diet).\n\n      Non-inclusion criteria\n\n        -  Patients receiving Maraviroc\n\n        -  Patients receiving immune suppressing drugs\n\n        -  Ongoing opportunistic, bacterial or viral infection\n\n        -  CRP \u2265 10 mg/mL\n\n        -  Co-infection with HCV (except if HCV cure), chronic HBV infection with active\n           replication of HBV\n\n        -  Indication for a treatment with statins\n\n        -  Pregnancy\n\n        -  CPK >  3x Normal values\n\n        -  ALT or AST > 2x Normal values\n\n        -  TG > 4 mmol/L\n\n        -  DFG < 60 mL /min/1.73 m2\n\n        -  Personal or familial history of genetic muscular disease\n\n        -  History of muscular or hepatic toxicity with a statin or a fibrate\n\n        -  Liver disease (TP < 70%).\n\n        -  Hypothyroidism\n\n        -  Concomitant treatment with : K\u00e9toconazole, Itraconazole, Ciclosporine, Erythromycine,\n           Cim\u00e9tidine, Quinidine, Diltiazem, V\u00e9rapamil, systemic corticosteroids, Ph\u00e9nobarbital,\n           Ph\u00e9nyto\u00efne, Carbamaz\u00e9pine, Rifampicine, Lansoprazole\n\n        -  Vaccination during the study\n\n      Intervention Rosuvastatin (20 mg/d per os) Intervention duration: 3 months Follow-up for 3\n      additional months\n\n      Statistical methods Bilateral Two-sided paired Wilcoxon to analyze the variation in the\n      proportion of CD8 T lymphocytes that co-express CD38 and HLA-DR at month 3 (primary\n      outcome).\n\n      The evolution of parameters of interest  between 2 visits will also be analyzed using\n      bilateral two-sided paired Wilcoxon test. Statistical significance will be considered for p<\n      0.05.\n\n      Substudies\n\n      Estimated planning or Study / Trial timetable Trial/study start date: April 2012 Enrolment\n      period: 12 months Subject participation duration: 6 months Total trial/study duration: 18\n      months Estimated study/trial completion date: October 2013 [default date: date of last\n      follow-up of last included patient, else justify the chosen date: date of \"gel de la base de\n      donn\u00e9es\", date of end of substudies analyses (think to delay for sampling transport,\n      duration of technical analyses)]\n\n      Study / Trial design Phase II open-label pilot bicentric non comparative study. Patients\n      eligible will receive Rosuvastatin for 3 months while continuing antiretroviral therapy.\n      Patients will be followed-up 3 additional months after stopping the study drug (on-off\n      design)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  HIV-infected patients receiving a combination of antiretroviral therapy for at least\n             24 months, unchanged since at least 18 months, exhibiting plasma HIV-RNA level below\n             20 copies and  circulating CD4 T cell count below 500/mm3\n\n          -  No indication for a treatment with statins (LDL cholesterol < 4.1 mmol/L under stable\n             diet).\n\n        Exclusion Criteria:\n\n          -  Patients receiving Maraviroc\n\n          -  Patients receiving immune suppressing drugs\n\n          -  Ongoing opportunistic, bacterial or viral infection\n\n          -  CRP \u2265 10 mg/mL\n\n          -  Co-infection with HCV (except if HCV cure), chronic HBV infection with active\n             replication of HBV\n\n          -  Indication for a treatment with statins\n\n          -  Pregnancy\n\n          -  CPK >  3x Normal values\n\n          -  ALT or AST > 2x Normal values\n\n          -  TG > 4 mmol/L\n\n          -  DFG < 60 mL /min/1.73 m2\n\n          -  Personal or familial history of genetic muscular disease\n\n          -  History of muscular or hepatic toxicity with a statin or a fibrate\n\n          -  Liver disease (TP < 70%).\n\n          -  Hypothyroidism\n\n          -  Concomitant treatment with : K\u00e9toconazole, Itraconazole, Ciclosporine, Erythromycine,\n             Cim\u00e9tidine, Quinidine, Diltiazem, V\u00e9rapamil, systemic corticosteroids, Ph\u00e9nobarbital,\n             Ph\u00e9nyto\u00efne, Carbamaz\u00e9pine, Rifampicine, Lansoprazole\n\n          -  Vaccination during the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01874743", 
            "org_study_id": "IMEA 043 CESAR"
        }, 
        "intervention": {
            "arm_group_label": "Rosuvastatine 20 mg", 
            "description": "All patients must take 20mg/day of rosavastatin during 3 months", 
            "intervention_name": "Rosuvastatin 20 mg/day", 
            "intervention_type": "Drug", 
            "other_name": "Crestor ,(ZD 4522)"
        }, 
        "intervention_browse": {
            "mesh_term": "Rosuvastatin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HIV,", 
            "Rosuvastatine,", 
            "Antiretroviral therapy"
        ], 
        "lastchanged_date": "June 11, 2013", 
        "location": [
            {
                "contact": {
                    "email": "laurence.weiss@egp.aphp.fr", 
                    "last_name": "Laurence Weiss, PHD,MD", 
                    "phone": "56093299", 
                    "phone_ext": "+331"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75015"
                    }, 
                    "name": "HEGP"
                }, 
                "investigator": {
                    "last_name": "Laurence Weiss, PHD,MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "pauline.campa@sat.aphp.fr", 
                    "last_name": "pauline Campa, MD", 
                    "phone": "49283044", 
                    "phone_ext": "+331"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75012"
                    }, 
                    "name": "St Antoine Hospital"
                }, 
                "investigator": {
                    "last_name": "Pierre-Marie Girard, PHD,MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pilot Study of the Impact of Rosuvastatin Administration on Residual Chronic Immune Activation Under Antiretroviral Therapy: CESAR (Crestor En Sus Des AntiR\u00e9troviraux)", 
        "overall_contact": {
            "email": "laurence.weiss@egp.aphp.fr", 
            "last_name": "Laurence Weiss, PH,MD", 
            "phone": "56093299", 
            "phone_ext": "+331"
        }, 
        "overall_official": {
            "affiliation": "HEGP", 
            "last_name": "Laurence Weiss, PH,MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To evaluate, in HIV-1 infected patients receiving effective antiretroviral therapy, the effect of the addition of Rosuvastatin (dose of 20mg/day) for 3 months, on CD8 T cell activation as assessed by the proportion of peripheral CD8 T cells that co-express the activation markers CD38 and HLA-DR", 
                "measure": "CD8 T cell activation", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "proportion of peripheral CD8 T cells that co-express the activation markers CD38 and HLA-DR", 
                "measure": "Coexpress activation markers", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01874743"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "\u2022\tChanges from baseline to month 3 (on rosuvastatin) and from month 3 to month 6 (off rosuvastatin) in levels of CRP-HS, IL-6, soluble CD14 Changes from baseline to month 3 (on rosuvastatin) and from month 3 to month 6 (off rosuvastatin) in the proportion of CD4 T cells expressing HLA-DR or  Ki67 activation markers and in the proportion of CD8 T cells expressing HLA-DR and/or CD38 or  Ki67 activation marker", 
                "measure": "Rosuvastatin administration (on and off)on biomarkers activation", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "\u2022\tRelationship between the levels of T-cell activation and of plasma HIV-RNA levels at a detection level of 3 copies/mL", 
                "measure": "Relationship between the levels of T-cell activation and of plasma HIV-RNA (ultrasensible measure)", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Changes in CD4 T-cell count between baseline and month 3 \u2022\nChanges in the CD4/CD8 ratio between baseline and month 3 and between month 3 and month 6", 
                "measure": "CD4 T-cell count and on the CD4/CD8 T-cell ratio", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "\u2022\tChanges from baseline to month 3 (on rosuvastatin) and from month 3 to month 6 (off rosuvastatin) in levels of HDL and LDL cholesterol", 
                "measure": "Lipids profiles on and off rosuvastatine association", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "To evaluate the tolerance of Rosuvastatin at the dose of 20 mg/day (Number of patients with adverse events grade > 2)", 
                "measure": "Tolerance of Rosuvastatine", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Institut de M\u00e9decine et d'Epid\u00e9miologie Appliqu\u00e9e - Fondation Internationale L\u00e9on M'Ba", 
        "sponsors": {
            "collaborator": {
                "agency": "Sidaction", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Institut de M\u00e9decine et d'Epid\u00e9miologie Appliqu\u00e9e - Fondation Internationale L\u00e9on M'Ba", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}